GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Deferred Tax

Thiogenesis Therapeutics (TSXV:TTI) Deferred Tax : C$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Thiogenesis Therapeutics's change in deferred tax for the three months ended in Sep. 2024 was C$0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.

Thiogenesis Therapeutics Deferred Tax Historical Data

The historical data trend for Thiogenesis Therapeutics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Deferred Tax Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23
Deferred Tax
- - - - -

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Thiogenesis Therapeutics Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics Deferred Tax Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Deferred Tax
Comparable Companies
NEOE:BMND TSXV:GSD XCNQ:DOSE TSX:HBP TSX:BCT XCNQ:PHRM XCNQ:TELI XCNQ:MDMA TSXV:NRX TSXV:SBM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TTIPF:USA Q8M:Germany
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Website
https://www.thiogenesis.com
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder